Refine by
Patient Identification Articles & Analysis
39 news found
Beyond academic research and transplantation applications, CD Genomics' HLA typing solutions hold great promise in pharmaceutical drug development. They facilitate the identification of patient cohorts with specific HLA alleles, essential for developing targeted therapies. ...
” Cellworks Precision Drug Development: Clinical Stage Clinical Trial Biosimulation: By biosimulating clinical trials, the Cellworks Platform may be able to predict human clinical response to pharmaceutical agents in just weeks, delivering critical insights years ahead of a traditional clinical trial. Patient cohorts are selected from the Cellworks ...
“As we continue to expand our clinical research program, we’re looking forward to improving our trial recruitment efforts with more accurate patient screening and identification, and ultimately, increasing patient access to trials and care.” The partnership will allow Gastro Health physicians to leverage Iterative ...
Geneva, Switzerland – October 26th, 2022, STALICLA SA, a precision neuroscience clinical stage biotech, advancing the first precision medicine platform (DEPI) for patients with Neurodevelopmental Disorders (NDDs), today announced first patient visits in its new STA-B-001 clinical observational-biosampling study in Spain and USA. ...
BySTALICLA
Medical Director Jay Pathmanathan, MD, PhD, discussed how the company has applied its machine learning platform to standard electroencephalography (EEG) data to detect electrical disturbances in the brain that may predict cognitive decline and explain variability in disease course for patients with Alzheimer's disease. Pathmanathan's presentation focused on research he ...
Cost is the main reason to avoid or stop insulin pump usage, emphasising the importance of patient-centric reimbursement policies for diabetes patients. Managing Type 1 diabetes takes considerable time and effort, and the healthcare stakeholders should not overlook the burden of care on patients’ quality of life. ...
The Company’s platform includes epidemiologic, phenotypic, and genetic data that reflects a global population, as well as a biobank of patients’ blood samples and cell cultures. CENTOGENE believes this represents the only platform focused on comprehensive analysis of multi-level data to improve the understanding of rare hereditary diseases. It allows for better ...
Cerapedics, a private ortho-biologics company, today announced that results from a clinical trial evaluating i-FACTOR Peptide Enhanced Bone Graft in non-instrumented lumbar fusion surgery has been published in the May 2020, Volume 20, Issue 5 print of The Spine Journal as the lead article. The data demonstrate that elderly patients in Denmark treated with i-FACTOR bone graft plus local bone had a ...
Synchron and Mount Sinai Hospital in New York Advance Industry-First FDA-Approved Clinical Trial for Brain-Computer Interface in U.S. Paralysis is a devastating condition for more than 5 million patients in the United States Synchron, an endovascular brain-computer (BCI) interface company, today announced the enrollment of the first patient in the US clinical trial, COMMAND, for patients ...
As new lumbar spinal stenosis (LSS) procedures become available, practices are evolving the way they collaborate and work together to optimize patient care. The mild® Procedure’s patient selection process is quite simple, but requires imaging review, which is often not a part of Advanced Practice Providers’ (APP) traditional education. ...
This collaboration is expected to identify biomarkers of response to refine patient selection to guide and accelerate the clinical development of Cyclerion’s investigational therapeutics for neurological and neuropsychiatric diseases associated with cognitive impairment. Ariana Pharma’s proprietary KEM® (Knowledge Extraction and Management) eXplainable Artificial ...
Lymphatic Research and Biology Publishes Data on PREVENT, the Largest Randomized Trial to Assess Lymphedema Prevention L-Dex Technology Provides a New Standard Approach for Prevention of Cancer-Related Lymphedema ImpediMed Limited (ASX: IPD), a global medical technology company using bioimpedance spectroscopy (BIS) to generate powerful data to maximize patient ...
Anteris Technologies Ltd (ASX: AVR) reports the first-in-human DurAVR™ THV study met or exceeded its interim study objectives. At the 30-day follow up point, the first five patients of the planned 10-patient study showed: All five subjects continued to do well with no reported adverse events (no death, stroke, myocardial infarction, reintervention). An average 86% improvement in mean ...
” It is estimated that more than 15,000 oncology clinical trials are actively recruiting patients; however, fewer than 1 in 30 patients participate in a clinical trial. Limited trial site resources make it time-consuming to identify eligible patients, especially as trial protocols increase in complexity. The Deep Lens technology and other ...
Nyxoah SA (Euronext Brussels/Nasdaq: NYXH)(“Nyxoah” or the “Company”), a medical technology company focused on the development and commercialization of innovative solutions to treat Obstructive Sleep Apnea (OSA), today provided a general corporate update. 2021 Highlights Implanted first U.S. patient in the DREAM IDE pivotal study in December 2020; there are currently ...
“The partnership with Premier’s PINC AI, a trusted leader in healthcare technology, will support a key pillar of new early cancer detection technology – the identification of eligible patients through healthcare providers’ existing workflows.” “PINC AI augments clinical intelligence and helps ensure patients ...
Collaborative efforts aim to accelerate drug discovery and improve clinical success Agreement to utilize Exscientia’s AI-based capabilities and personalised medicine platform from target identification through patient selection Research will be focused on up to 15 novel small molecule candidates across oncology and immunology Exscientia will receive an ...
Infraredx, a Nipro Company, a pioneer in intravascular imaging for mapping coronary artery disease, announced today the enrollment of the first patient in its EXPANSE PTCA study (NCT04985773) at the Cardiology Associates of North Mississippi in Tupelo, Mississippi. The study will be conducted in the United States with the objective to evaluate safety and effectiveness of the ...
Unfortunately, this means that identifying patients for trials is more labor intensive and timelines are often shortened, making it difficult for staff to enroll the right patients at the right time. We look forward to leveraging Deep Lens’ technology and services so that we can continue to provide our patients with every resource possible ...
“We are committed to giving our patients every resource possible to aggressively fight their disease. Expanding our clinical research program, attracting more trials to our practice and identifying the right trials for the right patients right as they are diagnosed will help our practice serve and support our patients more effectively as ...